Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ARIA (Aria.AI) fluctuates 50.1% within 24 hours: Whale activity and surging trading volume drive drastic price swings

ARIA (Aria.AI) fluctuates 50.1% within 24 hours: Whale activity and surging trading volume drive drastic price swings

Bitget PulseBitget Pulse2026/04/12 16:02
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, ARIA's price rebounded from a low of $0.66551 to a high of $0.99898, currently sitting at $0.90923, reflecting a price swing of 50.1%. Trading volume increased significantly, reaching approximately $61.8 million in 24 hours, which is about 30% of the market cap, with a net outflow of $44,700 (driven mainly by CEX net outflows).

Analysis of Abnormal Market Movements

• Intensified whale wallet activity: On-chain data shows whale accumulation in the past 24 hours pushed the price from a low of $0.46365 to a high of $0.9576, with increased volatility accompanied by net outflows.

• Explosion in trading volume: Spot trading volume surged to $30–62 million, triggering a short squeeze-style rebound, mainly fueled by retail speculation and leveraged trading.

Market Views and Outlook

Market sentiment is divided, with the community mainly concerned about continued high volatility and potential risks (such as aftershocks from recent flash crashes). Discussions on platform X note, “It’s exhausting; similar events occur frequently, causing capital outflow.” Analysts highlight that a high turnover rate reflects speculative dominance, and that short-term volatility may persist, warning of the risk of whale sell-offs.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring. For information purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23